Does Semaglutide Raise Your Heart Rate? What Clinical Research Shows
A faster heartbeat is one of the more surprising things people notice after starting semaglutide or tirzepatide. You might feel it as a mild flutter, a sense that your heart is beating harder than usu
In this article
A faster heartbeat is one of the more surprising things people notice after starting semaglutide or tirzepatide. You might feel it as a mild flutter, a sense that your heart is beating harder than usual, or a slight increase in your resting pulse rate when you check it in the morning. For many people this is unsettling, especially if no one mentioned it beforehand.
The good news is that a modest increase in heart rate is a well-documented, consistently observed effect of GLP-1 receptor agonist medications, and for most people using them under medical supervision, it does not represent a dangerous change. Understanding what is actually happening, what the clinical trials measured, and when an increase warrants a call to your provider can help you navigate this side effect with confidence.
*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. The clinical data discussed in this article comes from trials conducted with FDA-approved branded versions of these drugs. Results may differ with compounded formulations. This article is for educational and informational purposes only and does not constitute medical advice. Consult your licensed healthcare provider before starting or adjusting any medication.*
---
What the Clinical Trials Actually Measured
GLP-1 receptor agonist trials routinely collect cardiovascular data, including resting heart rate measurements, as part of their safety monitoring. Across several large trials, a consistent pattern emerged: patients receiving semaglutide or tirzepatide experienced a small but measurable increase in resting heart rate compared to those receiving a placebo.
The STEP 1 trial, one of the foundational studies on once-weekly semaglutide 2.4 mg for weight management, enrolled more than 1,900 adults with overweight or obesity without type 2 diabetes. Participants receiving semaglutide experienced increases in resting heart rate from baseline, with a mean increase in the range of 2 to 4 beats per minute compared to placebo. The effect was present throughout the treatment period and was documented across all STEP trial phases. (Wilding JPH et al., N Engl J Med 2021;384:989-1002. PMID: 33567185)
The SELECT cardiovascular outcomes trial, which enrolled more than 17,000 adults with overweight or obesity and established cardiovascular disease, also tracked resting heart rate over time. Semaglutide was associated with a modest elevation in heart rate relative to placebo. Critically, despite this elevation, the semaglutide group demonstrated a 20 percent reduction in major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) compared to placebo. The modest heart rate increase did not translate into worse outcomes. (Lincoff AM et al., N Engl J Med 2023;389:2221-2232. PMID: 37979973)
Tirzepatide, which acts on both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor, showed a similar pattern in the SURMOUNT-1 trial. Participants receiving tirzepatide experienced increases in resting heart rate versus placebo across the 72-week treatment period, with the effect generally consistent across the 5 mg, 10 mg, and 15 mg dose groups. (Jastreboff AM et al., N Engl J Med 2022;387:205-216. PMID: 35658024)
The magnitude of the effect, roughly 2 to 5 beats per minute on average, is well below the threshold used clinically to define tachycardia (a resting heart rate above 100 beats per minute). For most people, this increase falls entirely within the normal range of resting heart rate variability.
---
Why GLP-1 Medications Affect Heart Rate
GLP-1 receptors are not located only in the pancreas and gut. Research has identified them in multiple organ systems, including the heart. They are expressed in the sinoatrial node (the heart's natural pacemaker), in cardiac muscle cells, and in blood vessels throughout the body.
When a GLP-1 receptor agonist binds to these receptors, it can influence the rate at which the sinoatrial node fires, which directly affects how fast the heart beats. This is thought to be a direct pharmacological effect of the drug class rather than a consequence of weight loss itself.
A secondary mechanism may also contribute. GLP-1 receptor activation in blood vessels causes vasodilation, or widening of blood vessels, which reduces peripheral vascular resistance. When resistance drops, blood pressure can fall slightly, and the cardiovascular system may compensate by increasing heart rate. This reflex response, called a compensatory tachycardia, is a normal physiological response to reduced vascular resistance.
Both mechanisms likely contribute to the heart rate increases observed in clinical trials, and the relative importance of each may vary between individuals.
---
What This Means in Practice
For most people, a resting heart rate increase of 2 to 5 beats per minute is not perceptible and has no meaningful impact on how they feel day to day. The heart adapts quickly to this small shift, and it typically does not limit physical activity or cause significant symptoms.
Some people do notice subjective symptoms, however. You might feel:
- A heart that seems to be beating harder or faster than normal, particularly in the first few days after an injection
- A mild flutter or pounding sensation when at rest, especially in the first few weeks of treatment
- Slightly elevated pulse readings if you monitor your heart rate regularly
The effect tends to be more noticeable in the 24 to 48 hours immediately following an injection, when blood levels of the medication peak.
---
When to Be Concerned
A modest heart rate increase from a GLP-1 medication is expected and, for the vast majority of people, clinically insignificant. However, there are circumstances where a faster heart rate warrants prompt attention.
Contact your healthcare provider if you experience:
- A resting heart rate consistently above 100 beats per minute
- Heart palpitations accompanied by dizziness, lightheadedness, or feeling faint
- Chest pain, chest pressure, or chest tightness alongside a faster heartbeat
- Shortness of breath at rest or with minimal activity
- An irregular heartbeat or feeling that your heart is skipping beats
- Rapid heart rate that persists for hours after your injection
---
Does the Increase Get Better Over Time?
The evidence from clinical trials suggests that the heart rate elevation tends to stabilize rather than progressively worsen over time. In the STEP trials, the increase observed early in treatment did not continue to climb throughout the full treatment duration. Most participants reached a new, slightly elevated steady state that remained consistent.
For individuals who experience noticeable symptoms early in treatment, those symptoms often diminish as the body adjusts, even when the underlying heart rate remains modestly elevated. Your cardiovascular system is remarkably adaptable, and a permanent resting rate of 65 beats per minute rather than 60 is unlikely to produce long-term discomfort for most people.
If you track your heart rate with a fitness device or smartwatch, you may notice the increase clearly. This is useful data to share with your provider. A written log of your resting heart rate readings, your injection schedule, and any symptoms you notice can help your provider distinguish between expected pharmacological effects and anything that warrants closer evaluation.
---
How Tirzepatide Compares
Tirzepatide, the dual GIP/GLP-1 receptor agonist used for weight management, produces a similar pattern of heart rate elevation. The SURMOUNT trials documented heart rate increases versus placebo across all tirzepatide dose levels, with effects comparable in magnitude to those seen with semaglutide.
Both medications work through overlapping mechanisms in the heart, which is why their cardiovascular profiles share this feature. From a practical standpoint, if you experienced a noticeable heart rate increase with one of these medications, it is reasonable to anticipate a similar effect with the other. This is not a reason to avoid either medication, but it is worth discussing with your provider when deciding which treatment is appropriate for your situation.
---
The Bottom Line
A modest increase in resting heart rate is a consistent, expected feature of GLP-1 receptor agonist therapy. Clinical trials measuring this effect found increases in the range of 2 to 5 beats per minute on average, well below clinically meaningful thresholds for most people. Importantly, larger cardiovascular outcome trials like SELECT found that despite this effect, people using semaglutide experienced better cardiovascular outcomes overall compared to those not using it.
Most people do not find this effect troublesome. Those who notice symptoms, particularly in the first few weeks of treatment or after dose increases, often find that those sensations improve as the body adjusts.
If your heart rate increase is severe, persistent, or accompanied by symptoms like chest pain, dizziness, or an irregular heartbeat, contact your healthcare provider. For everyone else, this is a known side effect worth being aware of, not a reason to avoid medically supervised weight management.
---
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Compounding Disclaimer: Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded semaglutide is not the same as, equivalent to, or interchangeable with FDA-approved semaglutide products (Ozempic, Wegovy, or Rybelsus). Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro or Zepbound).
Results Disclaimer: Individual results vary. Weight management outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.
Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Prescriva LLC (DBA Prescriva) is a management services organization and does not practice medicine or make clinical decisions.
Brand Disclaimer: Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by these companies.
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →
